Atlas Trials

Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Clinical trial NCT03301896 · TERMINATED

Trial details

NCT number
NCT03301896
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Solid Tumors
Start date
2018-01-31
Primary completion
2022-06-30
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.